Disulfide-incorporated lipid prodrugs of cidofovir: Synthesis, antiviral activity, and release mechanism

[1]  Claire Marie Filone,et al.  Identification of Small Molecules with Improved Potency against Orthopoxviruses from Vaccinia to Smallpox , 2022, Antimicrobial agents and chemotherapy.

[2]  M. Tay,et al.  Monkeypox: disease epidemiology, host immunity and clinical interventions , 2022, Nature Reviews Immunology.

[3]  A. Margaryan,et al.  Diverse variola virus (smallpox) strains were widespread in northern Europe in the Viking Age , 2020, Science.

[4]  D. Delaune,et al.  Drug Development against Smallpox: Present and Future , 2020, Antimicrobial Agents and Chemotherapy.

[5]  Jinming Hu,et al.  Disulfide-Based Self-Immolative Linkers and Functional Bioconjugates for Biological Applications. , 2019, Macromolecular rapid communications.

[6]  Qiang Liu,et al.  Screening and evaluation of potential inhibitors against vaccinia virus from 767 approved drugs , 2019, Journal of medical virology.

[7]  Shundong Cai,et al.  Tumor microenvironment responsive drug delivery systems , 2019, Asian journal of pharmaceutical sciences.

[8]  J. Schiffer,et al.  The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. , 2017, Blood.

[9]  D. Liotta,et al.  Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release. , 2016, Journal of medicinal chemistry.

[10]  Y. Mehellou,et al.  Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates. , 2016, Journal of medicinal chemistry.

[11]  D. Liotta,et al.  Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity. , 2016, Journal of medicinal chemistry.

[12]  D. Florescu,et al.  Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses , 2014, Expert review of anti-infective therapy.

[13]  Chulhun Kang,et al.  Disulfide-cleavage-triggered chemosensors and their biological applications. , 2013, Chemical reviews.

[14]  L. Wilson,et al.  Colloidal properties of single component naphthenic acids and complex naphthenic acid mixtures. , 2013, Journal of colloid and interface science.

[15]  G. Painter,et al.  First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses , 2012, Antimicrobial Agents and Chemotherapy.

[16]  Claire Marie Filone,et al.  Identification of a Pyridopyrimidinone Inhibitor of Orthopoxviruses from a Diversity-Oriented Synthesis Library , 2011, Journal of Virology.

[17]  K. Rubins,et al.  Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression , 2011, Antiviral research.

[18]  M. Grinstaff,et al.  Reduction-triggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[19]  K. Hostetler.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. , 2009, Antiviral research.

[20]  Guillermo Repetto,et al.  Neutral red uptake assay for the estimation of cell viability/cytotoxicity , 2008, Nature Protocols.

[21]  J. Sagartz,et al.  Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model , 2008, Proceedings of the National Academy of Sciences.

[22]  E. Clercq,et al.  Acyclic nucleoside phosphonates: a key class of antiviral drugs , 2005, Nature Reviews Drug Discovery.

[23]  Hassane Izzedine,et al.  Antiviral drug-induced nephrotoxicity. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  K. Hostetler,et al.  Comparison of the Antiviral Activities of Alkoxyalkyl and Alkyl Esters of Cidofovir against Human and Murine Cytomegalovirus Replication In Vitro , 2005, Antimicrobial Agents and Chemotherapy.

[25]  G. Painter,et al.  Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. , 2004, Trends in biotechnology.

[26]  K. Hostetler,et al.  Inhibitory Activity of Alkoxyalkyl and Alkyl Esters of Cidofovir and Cyclic Cidofovir against Orthopoxvirus Replication In Vitro , 2004, Antimicrobial Agents and Chemotherapy.

[27]  L. Maibaum,et al.  Micelle Formation and the Hydrophobic Effect , 2004, cond-mat/0402107.

[28]  E. De Clercq.  Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections , 2003, Clinical Microbiology Reviews.

[29]  G. Painter,et al.  Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. , 2003, Antiviral research.

[30]  M. Bray,et al.  Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections , 2003, Antiviral research.

[31]  K. Hostetler,et al.  Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[32]  K. Hostetler,et al.  Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir , 2002, Antimicrobial Agents and Chemotherapy.

[33]  G. Ronco,et al.  Effects of tail alkyl chain length (n), head group structure and junction (Z) on amphiphilic properties of 1-Z-R-D,L-xylitol compounds (R = CnH2n+1). , 1999, International journal of pharmaceutics.

[34]  H. G. Howell,et al.  A practical synthesis of (S)-HPMPC , 1994 .

[35]  E. De Clercq,et al.  Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. , 1987, Antiviral research.

[36]  E. Lien,et al.  Effect of chain length on critical micelle formation and protein binding of quaternary ammonium compounds. , 1976, Journal of medicinal chemistry.

[37]  W. Freeman,et al.  Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.